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Abstract
One of the most important determinants of aging-related changes is a complex biological process emerged recently
and called “immunosenescence”. Immunosenescence refers to the inability of an aging immune system to produce an
appropriate and effective response to challenge. This immune dysregulation may manifest as increased susceptibility to
infection, cancer, autoimmune disease, and vaccine failure. At present, the relationship between immunosenescence
and lymphoma in elderly patients is not defined in a satisfactory way.
This review presents a brief overview of the interplay between aging, cancer and lymphoma, and the key topic of
immunosenescence is addressed in the context of two main lymphoma groups, namely Non Hodgkin Lymphoma
(NHL) and Hodgkin Lymphoma (HL). Epstein Barr Virus (EBV) plays a central role in the onset of neoplastic
lymphoproliferation associated with immunological changes in aging, although the pathophysiology varies vastly
among different disease entities. The interaction between immune dysfunction, immunosenescence and Epstein Barr
Virus (EBV) infection appears to differ between NHL and HL, as well as between NHL subtypes.
Keywords: Lymphoma, Lymphomagenesis, Immunosenescence, Ageing, Cancer
Background
Immunosenescence is a peculiar remodeling of the
immune system, caused by aging, associated with a wide
variety of alterations of immune functions. Mounting
biological evidence supports the potential clinical rele-
vance and impact of immunosenescence [1, 2]. Indeed, it
is has been implicated in pathophysiology of dementia,
frailty, cardiovascular diseases, and it is cause of in-
creased susceptibility to infectious disease, autoimmun-
ity and cancer. Hematological malignancies and
lymphoma are diseases that typically affect the elderly,
with a median age for the most common lymphoma
type, Diffuse Large B-cell Lymphoma (DLBCL), of >
70 years at diagnosis [3]. With the profound changes in
demographic profiles of western countries and a steadily
rising life expectancy, the number of elder patients with
lymphoma is increasing [4, 5].
Although the risk of developing these neoplasms is
higher in individuals with inherited predisposition or
subjected to environmental risk factors, most cases
cannot be associated with identifiable underlying
conditions. In fact, lymphomagenesis is proven to be a
molecularly complex process resulting in a broad cat-
egory of different lymphoproliferative disorders. On the
basis of histologic features, the pathogenetic events in-
volved in disease initiation and/or progression may vary
significantly [6].
Information regarding global burden of immunosenes-
cence in lymphomagenesis is limited and requires a de-
tailed understanding by the type of lymphoma
considered, because the mechanism might vary in differ-
ent specific cases [7].
This review aims to summarize the current state of
understanding about the role of immunosenescence and
development of lymphoma in older age.
We conducted a systematic research on PubMed,
without filtering the results by date, language, or article
type. Several studies have shown the potential to address
the problem; however, no reports were found of studies
in which clinically relevant relationships between the de-
velopment of lymphoma and the complex underlying
immunosenescence were elucidated.
Aging, cancer and immunosenescence
Age-related changes and cancer
It is commonly accepted that aging is the main risk fac-
tor for major chronic diseases such as cardiovascular
diseases, cancer and neurodegenerative diseases [8].
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Recently, nine candidate hallmarks of aging were de-
scribed in relation to genetic, epigenetic and environmen-
tal events [Table 1] [9, 10]. The resulting aging process
and the aging phenotype, characterized by loss of fitness,
create a favorable condition for aberrant neoplastic prolif-
eration [11]. The strong association between cancer and
age is supported by epidemiological data, indicating an in-
creased incidence of malignancies in elderly patients. In-
deed, about 55% of tumors affect subjects who are over
65 years of age https://seer.cancer.gov/archive/csr/
1975_2005/. Aging reflects the sum of all changes accu-
mulating with time by effect of genetic and environmental
causes [12, 13]. The more prolonged exposure to carcino-
gens in older people and the increase in mutational load,
epigenetic gene silencing, telomere dysfunction, unre-
stricted replicative potential, altered stromal milieu, apop-
tosis evasion, all contribute to an altered environment that
promotes neoplastic proliferation [14–17].
Biological basis of immunosenescence
Among the spectrum of hallmarks, the changes of the
immune response during aging now emerge as an
expanding field of research, supported by copious ex-
perimental data [18]. Immunosenescence is a complex
biological process that occurs in both the innate and
adaptive components of the immune system [19]. Most
of the effector functions of neutrophils, monocyte/
macrophage lineage and natural killer (NK) cells
decrease, concomitantly with a basal activation state
[20–22]. Chronic antigenic stimulation probably under-
lies the marked changes in the adaptive immune system
[23]. The ultimate consequence is a shift from loss of di-
versity of the T-cell receptor (TCR) repertoire to an in-
crease in number of exhausted CD28− T cells, and
profound functional changes in CD4 T cell subpopula-
tions [8, 24, 25]. Together, these alterations of the innate
and adaptive immunity favor the gradual development of
a state of chronic inflammatory process called “inflam-
maging” [26, 27]. It is not perfectly clear if the state of
slightly raised inflammatory mediators is really part of
immunosenescence or an independent phenomenon
with additive effects on morbidity and mortality [28, 29].
To this regard, a basic characteristic of the immune sys-
tem is plasticity, the capability of immune cells to
undergo modification and adapt to different situations
[30]. There is limited knowledge on whether immunose-
nescence is really associated with detrimental clinical
outcomes or whether changes in immune parameters of
older people reflect adaptive responses to the clinical
and immunological history of the subject [31–33].
Therefore, it is necessary to reconsider some conclusions
on the basis of many disparate findings in the literature.
Against certain generalizations related to immunosenes-
cence, context-dependent immune ageing processes
need to be identified, with a detailed understanding of
those diseases that are of major health interest [34].
Immunosenescence and defects in cancer protection
It is well known that both the innate and the adaptive
immune system protect the host against carcinogen-
esis by a process called “immunosurveillance”. By
means of this process, the immune cells identify and
eliminate cancerous cells before tumor develops [35].
In some cases, the functional ability of immunosur-
veillance cannot prevent the tumors from escaping
and growing because the pressure exerted by the im-
mune system can select many variants of resistant
tumor cells. Immunosenescence can be considered as
an additional factor which further promotes the tu-
mor’s escape mechanism [36].
Dysregulated function of the immune system affecting
older people involves both innate and adaptive parts,
with many mechanisms sharing molecular pathways im-
plicated in the carcinogenesis process [37]. Among
age-related alterations, the impairment of apoptotic cell
death and the immunosuppressive role of some cyto-
kines, such as interleukin-10 (IL-10) and transforming
growth factor-β (TGF-β) which increasing in the elderly,
could be relevant in the relationship between ageing and
risk of tumor development [38, 39]. Therefore, immuno-
senescence may be linked to immune tolerance and con-
tribute to an increased incidence of cancer with age.
Some evidence suggests that tumor-induced immuno-
suppression, through active mechanisms that can avoid
or evade immune attack, might be more effective in age-
ing. Regarding the Fas ligand/Fas receptor (FasL/FasR)
mechanism, the increased FasR expression observed in
aged leukocytes might facilitate the immune escape of
tumors expressing FasL [40]. A further example is the
release of immunosuppressive cytokines by tumor cells
such as TGF- β, IL-10 and others, that can suppress T
cell responses and, in old subjects, may synergize with
immunosuppressive cytokines overproduced by aged
leukocytes [38].
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Immunosenescence and non-Hodgkin lymphoma
Non-Hodgkin lymphoma and aging
The current available data focuses on B cell Non
Hodgkin Lymphomas (NHL), which represent more
than 90% of lymphoid neoplasms worldwide [41]. They
are a heterogeneous group of clonal tumors of mature B
cells that have distinctive clinical and biological behav-
iors [42–44]. NHL subtypes tend to mimic stages of nor-
mal B cell differentiation so that they can be classified
according to the corresponding normal stage. In the
context of NHL, a stepwise increase in the incidence of
DLBCL over the last 20 years has been observed, par-
ticularly for patients older than 65 years [45]. The
current increase in life expectancy naturally results in a
higher number of elderly patients. Between lymphoma
and aging, a complex interplay can be described [46]. B
cell NHLs develop by a multistep process closely related
to normal B cell counterpart that can be favored with
aging [47]. Many potential factors can play a role in lym-
phomagenesis in the elders. As with all other cancer
types, chronological ageing is associated with the
accumulation of DNA damage particularly in stem cells
[48]. Recently, significant large scale studies by
whole-exome sequencing data have reported age-related
clonal hematopoiesis, with somatic mutations in genes
that are recurrently mutated in hematological neoplasms
[49–51]. Also, epigenetic abnormalities that have a role
in lymphoma development as in leukemia can accumu-
late with aging [52].
Immunosenescence, chronic infection and
lymphomagenesis in non-Hodgkin lymphoma of the
elderly
In addition to abnormal genetic events, also age-related
impairment in cancer protection is expected to promote
B cell lymphomagenesis. The phenotype called “immu-
nosenescence” is associated with a complex dysfunction
that increases sensitivity to infections. Chronic infection
with Cytomegalovirus (CMV) and EBV in the elderly
caused by restricted T cell response can alter the B cell
immune repertoire, leading to infection-linked diseases
as well as some types of lymphoma [53]. It is known
how B lymphomagenesis can be driven by microbial
pathogens through chronic antigenic stimulation, and
several examples are available in this regard. Some lym-
photropic oncogenic viruses, EBV, Human-Herpesvirus-
8 (HHV8), Human T-lymphotropic virus HTLV1) are
directly responsible for lymphoid cell neoplastic trans-
formation and are causative agents of different histologic
entities, with varying aggressiveness. Other pathogens,
indirectly via chronic inflammation of the mucosa-asso-
ciated lymphoid tissue (MALT), have been associated
with MALT Marginal Zone Lymphoma in various organs:
Helicobacter pyloric, Campylobacter jejeuni, Chlamydia
psittaci and Borrelia burgdorferi [54, 55]. Also, a causal re-
lationship between Hepatitis C Virus (HCV) and NHL has
been demonstrated and the most plausible molecular
mechanism is lymphoma development by continuous anti-
genic stimulation. However, an increased incidence of NHL
hystotypes linked to infections in the elderly has not been
reported. A specific provisional entity in 2008’s World
Health Organization (WHO) classification of tumors of
hematopoietic and lymphoid tissue has been described as
“EBV-positive DLBCL of the elderly” (EBV-DLBCL-E) [56,
57]. This lymphoproliferative disease occurs in absence of
any primary or secondary immune deficiency and tends to
have a post germinative center (GC)-phenotype and a poor
prognosis [58]. The possible pathogenetic mechanism is
lymphoma development as a consequence of immunose-
nescence and as part of the normal aging process, with a re-
duction in T cell repertoire. Immune modification can
facilitate a second genetic event favored by EBV chronic in-
fection in genetically instable B cell compartment.
EBV-positive DLBCL thus represents a significant proof of
the complex interplay between immunosenescence and
lymphoma, and supports the leading role played by viruses
in this setting. In 2016’s updated WHO classification of
lymphoid neoplasia, this entity is now recognized as defin-
ite and the term “elderly” has been substituted by “not
otherwise specified” (NOS) in such that these lymphomas
can be present in younger patients as well [59]. In this pa-
tient group, EBV-positive DLBCLs usually have a positive
outcome in contrast to EBV-DLBCL-E [60]. Nevertheless,
EBV-DLBCL-E is a relatively rare lymphoid malignancy (<
5% in Western countries) and cannot explain the increased
incidence of B-NHL in older patients.
Diffuse large B cell lymphoma and aging-related
molecular changes
Few studies have investigated whether a signature of
aging can be seen in B cell NHL. Histopathologic fea-
tures of DLBCL do not differ between age groups. How-
ever, studies of gene expression profiling (GEP) have
described a higher frequency of activated B cell (ABC)
DLBCL subtype in the elderly together with an increased
B-cell lymphoma-2 (BCL2) expression and more
genomic abnormalities [61–63]. These specificities can
provide a basic understanding of the biological and clin-
ical characteristics as well as the worst prognosis of
DBCL in older patients.
Potential molecular alterations based on age in DLBCL
patients have been described. Beheshti et al. identified
significant age-related molecular changes after examin-
ing global transcriptome DLBCL data from The Cancer
Genome Atlas, and striking transcriptional differences
were associated with decreased metabolism and telo-
mere dysfunction. The greatest functional changes oc-
curring in older populations were related to key genes
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that strongly regulate the immune system [64]. These
molecular factors influence tumor size and tumor pro-
gression in older DLBCL patients, but it is not clear if
these findings may improve our understanding of lym-
phomagenesis as well as the role of immunosenescence.
Immunosenescence and Hodgkin’s lymphoma
Epidemiology and biology of Hodgkin lymphoma
Classical Hodgkin Lymphomas (cHL) are unusual B
cell-derived malignancies and the majority of them
manifest clinically in young adults, even though a
bimodal age curve is described, with a second peak later
in life. They account for 30% of all lymphomas. In con-
trast with NHL, their absolute incidence has not appar-
ently changed and no increase has been observed in
aged population [65, 66].
Neoplastic tissues include rare malignant Hodgkin and
Reed-Stenberg (HRS) cells within an extensive but inef-
fective inflammatory/immune cell infiltrate composed of
macrophages, eosinophils, mast cells and T cells [67].
Although HRS cells have lost expression of certain B cell
surface proteins and, particularly, B cell receptors, they
do not die by apoptosis, so alternative pathways for sur-
vival and growth are exploited [68]. Key strategies lever-
age different mechanisms, such as nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB)
signaling, Janus kinase/signal transducers and activators
of transcription (JAK/STAT) pathway, AP-1 transcrip-
tion factor, tumor necrosis factor (TNF) receptor family
protein expression but latest data support the major role
of immune evasion [69–72]. Malignant HRS cells escape
immune attack using multiple stratagems, including en-
hanced PD-1 signalling, secretion of soluble factors with
inhibitory effects such as IL-10 and recruitment of abun-
dant immunosuppressive C-C chemokine receptor type
4 regulatory T-cells (CCR4 Tregs) [73–75]. These fea-
tures are highly informative for the position of immuno-
surveillance to tumor cells in cHL pathogenesis.
Epstein-Barr virus and lymphomagenesis of Hodgkin
lymphoma in the elderly
The biology and origin of cHL can be related to the
oncogenic role of EBV [57]. EBV is a human virus, etio-
logically linked to a significantly wide range of lympho-
proliferative diseases of B, T and NK cells. The role of
EBV as growth-transforming agent is not linked to a sin-
gle and simple oncogenic mechanism, but to a complex
interplay between different patterns of viral gene expres-
sion, cellular genetic changes and immunity of the host.
cHL is one of the major B cell malignancy types linked
to EBV although it can occur in EBV-positive and nega-
tive form, both in apparently immunocompetent
subjects [76]. But virus-specific immune surveillance
should not be viewed as secondary. Indeed, immune
impairment enhances lymphoma risk and the incidence
of lymphoma and proportion of cHL cases that are
EBV-positive are increased in Human Immunodeficiency
Virus (HIV)-infected individuals. Furthermore, the pro-
portion of cHL cases associated to EBV varies signifi-
cantly with age and is more prevalent in older adults.
The cases arising in the elderly appear as a different dis-
ease compared to cHL in young patients [77]. There are
more patients who are found in advanced stages with
B-symptoms and poor performance status, outlining a
different pattern of histology subtypes with mixed cellu-
larity that appear more evident if compared with youn-
ger individuals. EBV-associated disease was recognized
as a poor prognostic factor and was also associated with
an advanced-stage lymphoma [78]. The peak of cHL in
adults may be attributed, at least partially, to senescence
of EBV immunity and to an increased viral load. The
prominent role of immunosenescence compared to
other aging-related factors can explain why the increase
in incidence of diffuse large B cell lymphoma over the
last decades due to aging population has not been
reflected in the incidence of cHL, which appears to stay
constant [79]. cHL of the elderly, because of morpho-
logical features and association with EBV, is probably
similar to cHL during HIV infection. In HIV-infected
people, the incidence of cHL is 10-fold higher than in
the general population, and the development of
HIV-related cHL is not dependent on profound T-cell
depletion, but only a modest impairment of CD4 lym-
phocytes is sufficient to elevate EBV viral load in the B
cell system [80]. Indeed, after the introduction of Highly
Active Antiretroviral Therapy (HAART) in the treat-
ment of HIV infection, cHL incidence among HIV–in-
fected cohorts has slightly increased [81, 82]. These
common features between lymphomagenesis of cHL in
older patients and in HIV-infected subjects reflect many
similarities between biology of immunosenescence in
aging and residual immunological defects in treated HIV
infection [83]. Indeed, long-term therapy with HAART
is associated with an increased risk of complications
with degenerative nature and of cancer types that are
similar to those observed among the elderly [84].
Other links between immunosenescence and
lymphoma in the elderly
In addition to the role of immunosenescence in the patho-
genesis of lymphomas, still little is known about the inter-
actions between aging immune system changes and other
aspects of lymphoma biology as well as lymphoma man-
agement. Recently, some reports have emerged on the
possible role of immunosenescence in the progression of
cancer; furthermore, immunosenescence-associated
changes are exacerbated by chemotherapy. Older patients’
immune background could play a critical role for higher
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risk of infections as a side effect of chemotherapy. Immu-
nosenescence might, therefore, contribute to negative out-
comes in patients with lymphoma and could be a target
for therapy.
Finally, whether, or to what extent, immunosenescence
plays a role in response or toxicity to anti-neoplastic
therapy with immune checkpoint inhibitors is still a
matter of debate, representing a relevant unmet need.
Conclusion
The phenomenon of immunosenescence plays an essen-
tial, but poorly defined, role in the development of
lymphoma. Older people are a heterogeneous portion of
population that experiences various degrees of ageing
and immune system remodeling. In addition, the mech-
anism of lymphomagenesis might vary by the type of
lymphoma considered. In this setting, impairment of im-
mune functions can predispose to development of
lymphoma related to oncovirus infection, through re-
duced ability to clear infectious agents, chronic antigenic
stimulation, lymphoma growth, immune evasion. EBV
plays a central role in the onset of neoplastic lympho-
proliferation, associated with immunological changes in
aging. Current clinical and epidemiological findings,
confirmed by molecular evidence, have generally re-
vealed the oncogenic role of EBV only in a small size
sample of lymphoma subtypes of elderly: EBV-
DLBCL-E and cHL [85–87].
Since aging, as well as immunosenescence, is heteroge-
neous, both inter-individually and intra-individually, the
assessment of this decline should be done individually
and adapted not solely on chronological age. Currently,
aging assessment is clinical and based upon a geriatric
evaluation [88–90]. The challenging question is to find
key biomarkers of immunaging that can help to better
estimate the role of the aging phenotype and to include
a measure of immunosenescence in studies by collecting
data on elderly patients with cHL and EBV-DLBCL [91].
Thus far, of all the age-associated immune parameters
found to be informative, it is not possible to select those
that are crucial for clinical relevance.
Looking to the future, the new understanding of
immunosenescence will have an impact on the treatment
of lymphomas to further individualize therapy. Lastly,
for research agenda, HIV-infected patients receiving
HAART provide a model for a better understanding of
how immune dysfunction with limited immune defi-
ciency can promote lymphoma development [92].
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